Aldo Trylesinski

机构：Intercept Pharmaceuticals (United States)

发表论文 79 篇 · 总被引 2273 次 · h-index 20

代表论文

• Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis (2021 · Journal of Hepatology · 被引 369)
• An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD) (2024 · Nature Metabolism · 被引 259)
• Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis (2023 · ˜The œLancet. Gastroenterology & hepatology · 被引 205)
• Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study (2021 · Journal of Hepatology · 被引 161)
• Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis in five European countries in 2018: A cost‐of‐illness analysis (2021 · Liver International · 被引 145)
• Knowledge of liver fibrosis stage among adults with NAFLD / NASH improves adherence to lifestyle changes (2022 · Liver International · 被引 55)